Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Colorectal Neoplasms Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for Colorectal Neoplasms. Eligibility criteria explained in plain English.

TrialFinderData lists 5 Colorectal Neoplasms clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 20% (1 studies); the largest phase groups are Phase 3: 1, Phase 1: 1, Phase 1 / Phase 2: 1, Phase 2 / Phase 3: 1.

Research is led by Cancer Research UK (2), The Netherlands Cancer Institute (1), Janssen Research & Development, LLC (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy (drug, 1 trial), followed by Hepatic arterial infusion pump (HAIP), Systemic therapy (standard of care).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
1
Phase 3 Trials
4
Sponsors

Track Colorectal Neoplasms trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 3NCT06857773

Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump...

The goal of this randomized clinical trial is to investigate induction treatment with Hepatic Arterial Infusion Pump therapy combined with systemic therapy (HAIP-SYST) in...

Sponsor: The Netherlands Cancer InstituteEnrolling: 3061 location
RECRUITINGPhase 1NCT07107230

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with...

Sponsor: Janssen Research & Development, LLCEnrolling: 3809 locations
RECRUITINGPhase 1 / Phase 2NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other...

Sponsor: Cancer Research UKEnrolling: 1505 locations
RECRUITINGPhase 2 / Phase 3NCT05770102

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With...

This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung...

Sponsor: Cancer Research UKEnrolling: 3020 locations
RECRUITINGPhase 4NCT07158164

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and...

Sponsor: Rutgers, The State University of New JerseyEnrolling: 10012 locations

Frequently Asked Questions

There are currently 5 clinical trials for Colorectal Neoplasms, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Colorectal Neoplasms, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Colorectal Neoplasms, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.